MétaCan
Menu
Back to cohort
Record W2269888391

Intrinsic resistance of prostate cancer to the BH3 mimetic ABT-737 is related to expression of the anti-apoptotic Mcl-1 and additional survival and apoptosis regulating pathways

2007· article· en· W2269888391 on OpenAlexaff
Jorg Michels, Heather Lockyer, Sindy Babinsky, Shannon Awrey, Martin Gleave

Bibliographic record

VenueMolecular Cancer Therapeutics · 2007
Typearticle
Languageen
FieldChemistry
TopicClick Chemistry and Applications
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsDU145LNCaPApoptosisCytotoxic T cellViability assayCytotoxicityCancer researchProstate cancerPharmacologyChemistryCell cultureCancerBiologyIn vitroMedicineInternal medicineBiochemistry
DOInot available

Abstract

fetched live from OpenAlex

A281 Background: ABT-737 is a novel and potent oral small molecule inhibitor of the anti-apoptotic Bcl-2 and Bcl-xL proteins. ABT-737 has substantial single agent or synergistic activity in myeloid/lymphoid malignancies and small cell lung cancer. Overexpression of Bcl-2/Bcl-xL is linked to prostate cancer progression, hence rendering Bcl-2 and Bcl-xL attractive therapeutic targets. The in vitro activities of ABT-737 in prostate cancer models and potential resistance mechanisms were investigated.
 Methods: Cytotoxicity of ABT-737 and potential synergism with apoptosis inducing stimuli was investigated in PC3, DU145, C42, LNCaP cell using cell viability assay. Expression of anti-apoptotic Bcl-2 members in PC cell lines was assessed by immunoblotting (IB) and related to cytotoxic effect of ABT-737. The effect of serum deprivation (SD) on ABT-737 cytotoxicity was assessed and explorative studies of potential ABT-737 resistance mechanisms under serum deprived growing conditions were conducted. The impact of Mcl-1 down regulation following transfection with specific antisense oligodeoxynuleotide (ODN) on ABT-737 induced cytotoxicity was evaluated.
 Results: ABT-737 had no to minor cytotoxic effect in tested PC lines (IC50 > 10μM, 72hours). Combination of ABT-737 with androgen-deprivation or cyctotoxic agents (paclitaxel, CDDP) caused no or mild additive effect (20-40%) in some but not other cell lines. In contrast, SD (72hours) exhibited pronounced synergistic activity with ABT-737 (IC50 0.5μM PC3/DU145/C42, 2.5μM LNCaP) but not the inactive enantiomer while no impact on cell viability by SD alone was noted. Expression signature of anti-apoptotic Bcl-2 proteins demonstrated that Mcl-1 was expressed in all PC lines on IB. Mcl-1 down regulation following antisense ODN markedly restored sensitivity to ABT-737 (IC50 2-3 μM) but not enantiomer in all but DU145 (IC50 5-10μM). Expression dynamics of pro-/anti-apoptotic Bcl-2 proteins, clusterin, PI3K, MAPK under normal and SD growing conditions indicated several potential mechanisms associated with ABT-737 resistance in PC.
 Conclusion: ABT-737 did not demonstrate single agent activity or meaningful additive/synergistic activity with commonly used therapeutic maneuvers in preclinical prostate cancer models. Sensitivity to ABT-737 appeared to be restored upon serum withdrawal in PC model. Multiple and cell line specific expression and alterations in signaling and apoptosis regulating proteins were associated with serum withdrawal. Our results identify Mcl-1 as an important determinant of ABT-737 resistance and validate Mcl-1 as potential therapeutic target in prostate cancer.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.007
Threshold uncertainty score0.520

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.266
Teacher spread0.250 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2007
Admission routes1
Has abstractyes

Explore more

Same venueMolecular Cancer TherapeuticsSame topicClick Chemistry and ApplicationsFrench-language works237,207